ACRP CCRA EXAM PREP/STUDY GUIDE
EXAM 2026-2027 QUESTIONS AND
CORRECT ANSWERS
What should be the first consideration when conducting a clinical
trial? - CORRECT ANSWER Subject welfare
What are expected or possible consequences of over-estimation
of recruitment potential? - CORRECT ANSWER - The trial will
overrun its projected timeline
- The
recruitment period will be prolonged and more sites may be
needed
- Thestudy will not have sufficient data within the required
timeframe and will be stopped because of lack of budget
When is the investigator allowed to deviate from the protocol? -
CORRECT ANSWER When there is an immediate hazard to a
patient.
If the investigator wanted to deviate from the protocol for an
immediate hazard to a patient, according to ICH E6 guidelines
who world they need to report the deviation and rationale to, if
appropriate? - CORRECT ANSWER - The Sponsor
- IRB/IEC
- Regulatory Authorities
,Which conditions should be fulfilled when enrolling a subject into
your trial? - CORRECT ANSWER - Subject meets all inclusion
criteria
- Subject has given written informed consent
You've been delegated to handle the storage and inventory of IP.
The study drug must be stored below 25C/77F. On a summer
Monday morning you discover that the temperature recording
machine in the storage room has failed so you doin't know what
the temperature has been over the weekend. You check the
current temperature; it's 24C/75F. What should you do? -
CORRECT ANSWER - Contact the Sponsor, explain what happened
and ask for instructions
- Set up a site staff meeting to conduct a root cause analysis
A protocol amendment was issued for a trial. Your site received
IRB approval for the amendment and wants to implement the
increase in PO dose for your trial subjects as identified in the
amendment trial subjects. As delegated consenting duties you
must reconsent trial subjects before being able to administer the
adjusted dose. You decide to only re-consent trial subjects who
are still taking the IP and not from the subjects woh already
completed their drug intake period. Is this allowed according the
E6 Guideline for GCP? - CORRECT ANSWER No, these subjects are
still enrolled in the trial and therefore need to be updated on any
changes to the protocol.
,A trial subject informs you she no longer wants to participant in
the trial. What should your course of action be? - CORRECT
ANSWER You ask if the patient wishes to share the reason why
she wants to leave the trial. If not, you exclude the subject from
the trial immediately.
A patient cannot recall the name of the heart condition
medication he took a few years ago. This is important information
for deciding whether the patient may be enrolled in a clinical trial
(IC/EC). What's your best course of action? - CORRECT ANSWER
You attempt to retrieve the patients medical history by contacting
previous caregivers and you wait for additional information
before enrollment.
Who has ultimate trial responsibility for each subject? - CORRECT
ANSWER The principle investigator.
A trial subject suffers from severe repeat headaches. Should this
adverse event be reported to the IRB? - CORRECT ANSWER No
What statements are true concerning an adverse drug reaction? -
CORRECT ANSWER - All noxious and unintended responses to a
medicinal product related to any dose should be considered as an
ADR
- An ADR suggests a relationship to trail medication
, - All ADRs must be documented
What Adverse Events (AEs) are Serious Adverse Events (SAEs)? -
CORRECT ANSWER - Any AE that results in death
- Any AE that results in inpatient hospitalization
- Any AE that is a congenital anomaly
During a study visit a patient tells the investigator that she visited
an emergency room and received intensive treatment for allergic
bronchospasm. Since the patient was in the emergency room for
only three hours, the investigator did not assess the event as
serious. Is this a correct assessment? - CORRECT ANSWER No, this
would be a medically important event and should be considered
serious
What data points minimally need to be reported by the site when
reporting an SAE, so that the sponsor can process the event? -
CORRECT ANSWER Identification of event, product, and trial
subject
During a visit with investigator, a subject reported feeling heart
palpitations for a brief period of time during the previous
evening. The heart palpitations resolved without reoccurrence.
The investigator considered these symptoms to be unrelated to
study drug. The next day, the subject told a fellow student that
he felt tired and was planning on taking a nap. Later, the subject
EXAM 2026-2027 QUESTIONS AND
CORRECT ANSWERS
What should be the first consideration when conducting a clinical
trial? - CORRECT ANSWER Subject welfare
What are expected or possible consequences of over-estimation
of recruitment potential? - CORRECT ANSWER - The trial will
overrun its projected timeline
- The
recruitment period will be prolonged and more sites may be
needed
- Thestudy will not have sufficient data within the required
timeframe and will be stopped because of lack of budget
When is the investigator allowed to deviate from the protocol? -
CORRECT ANSWER When there is an immediate hazard to a
patient.
If the investigator wanted to deviate from the protocol for an
immediate hazard to a patient, according to ICH E6 guidelines
who world they need to report the deviation and rationale to, if
appropriate? - CORRECT ANSWER - The Sponsor
- IRB/IEC
- Regulatory Authorities
,Which conditions should be fulfilled when enrolling a subject into
your trial? - CORRECT ANSWER - Subject meets all inclusion
criteria
- Subject has given written informed consent
You've been delegated to handle the storage and inventory of IP.
The study drug must be stored below 25C/77F. On a summer
Monday morning you discover that the temperature recording
machine in the storage room has failed so you doin't know what
the temperature has been over the weekend. You check the
current temperature; it's 24C/75F. What should you do? -
CORRECT ANSWER - Contact the Sponsor, explain what happened
and ask for instructions
- Set up a site staff meeting to conduct a root cause analysis
A protocol amendment was issued for a trial. Your site received
IRB approval for the amendment and wants to implement the
increase in PO dose for your trial subjects as identified in the
amendment trial subjects. As delegated consenting duties you
must reconsent trial subjects before being able to administer the
adjusted dose. You decide to only re-consent trial subjects who
are still taking the IP and not from the subjects woh already
completed their drug intake period. Is this allowed according the
E6 Guideline for GCP? - CORRECT ANSWER No, these subjects are
still enrolled in the trial and therefore need to be updated on any
changes to the protocol.
,A trial subject informs you she no longer wants to participant in
the trial. What should your course of action be? - CORRECT
ANSWER You ask if the patient wishes to share the reason why
she wants to leave the trial. If not, you exclude the subject from
the trial immediately.
A patient cannot recall the name of the heart condition
medication he took a few years ago. This is important information
for deciding whether the patient may be enrolled in a clinical trial
(IC/EC). What's your best course of action? - CORRECT ANSWER
You attempt to retrieve the patients medical history by contacting
previous caregivers and you wait for additional information
before enrollment.
Who has ultimate trial responsibility for each subject? - CORRECT
ANSWER The principle investigator.
A trial subject suffers from severe repeat headaches. Should this
adverse event be reported to the IRB? - CORRECT ANSWER No
What statements are true concerning an adverse drug reaction? -
CORRECT ANSWER - All noxious and unintended responses to a
medicinal product related to any dose should be considered as an
ADR
- An ADR suggests a relationship to trail medication
, - All ADRs must be documented
What Adverse Events (AEs) are Serious Adverse Events (SAEs)? -
CORRECT ANSWER - Any AE that results in death
- Any AE that results in inpatient hospitalization
- Any AE that is a congenital anomaly
During a study visit a patient tells the investigator that she visited
an emergency room and received intensive treatment for allergic
bronchospasm. Since the patient was in the emergency room for
only three hours, the investigator did not assess the event as
serious. Is this a correct assessment? - CORRECT ANSWER No, this
would be a medically important event and should be considered
serious
What data points minimally need to be reported by the site when
reporting an SAE, so that the sponsor can process the event? -
CORRECT ANSWER Identification of event, product, and trial
subject
During a visit with investigator, a subject reported feeling heart
palpitations for a brief period of time during the previous
evening. The heart palpitations resolved without reoccurrence.
The investigator considered these symptoms to be unrelated to
study drug. The next day, the subject told a fellow student that
he felt tired and was planning on taking a nap. Later, the subject
